赛诺菲

最新新闻

• Sanofi (SNY.US) has submitted a new indication for its long-acting RSV monoclonal antibody for marketing approval.
  Zhitong Finance · 2026/8/7
• TD Cowen Maintains Sanofi(SNY.US) With Hold Rating, Maintains Target Price $57
  \u5e02\u573a\u8d44\u8baf · 2026/8/31
• 公司公告
  Novavax | 8-K: Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
  SEC · 2025/11/4
• 评级变动
  J.P. Morgan Maintains SANOFI(SNYNF.US) With Hold Rating, Cuts Target Price to $106.77
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 评级变动
  Deutsche Bank Maintains SANOFI(SNYNF.US) With Buy Rating, Cuts Target Price to $107.69
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• Despite raising its earnings guidance in the new CEO's debut, Sanofi (SNY.US) saw its share price fall, as a pipeline drought of new drugs emerges as a critical vulnerability.
  Zhitong Finance · 2026/7/30
• 评级变动
  Berenberg Bank Maintains SANOFI(SNYNF.US) With Buy Rating, Raises Target Price to $119.02
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Sagimet Biosciences, Inc. Class A (SGMT) and Eli Lilly & Co (LLY)
  TipRanks · 2026/10/1
• 公司公告
  6-K: Sanofi Achieves Double - Digit Sales Growth in the Second Quarter, With a Steady Increase in Business Earnings per Share. 2025 Sales Guidance Is Now High Single-Digit Growth, At Upper End of Range
  SEC · 2025/7/31
• 评级变动
  J.P. Morgan Maintains SANOFI(SNYNF.US) With Hold Rating, Cuts Target Price to $106.48
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 评级变动
  Berenberg Bank Maintains SANOFI(SNYNF.US) With Buy Rating, Cuts Target Price to $117.81
  \u5e02\u573a\u8d44\u8baf · 2026/10/6
• 公司公告
  Sanofi | 6-K: Sanofi to Acquire Inhibrx, Inc., Adding Potential Best-in-Class Rare Disease Asset for Alpha-1 Antitrypsin Deficiency to Pipeline
  SEC · 2024/1/23
• Sanofi's (SNY.US) BTK inhibitor approved for market launch in China
  Zhitong Finance · 2026/9/3
• 评级变动
  RBC Capital Maintains SANOFI(SNYNF.US) With Hold Rating, Cuts Target Price to $89.91
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (OtherSNYNF), Amgen (AMGN) and BrightSpring Health Services, Inc. (BTSG)
  TipRanks · 2026/9/17
• 评级变动
  Jefferies Maintains SANOFI(SNYNF.US) With Buy Rating, Cuts Target Price to $112.08
  \u5e02\u573a\u8d44\u8baf · 2026/10/7
• 公司公告
  6-K: Sanofi to Acquire Vigil Neuroscience, Inc., Adding a New Investigational Medicine to Treat Alzheimer's Disease to the Neurology Pipeline
  SEC · 2025/5/22
• 评级变动
  BofA Securities Maintains SANOFI(SNYNF.US) With Hold Rating, Raises Target Price to $103.29
  \u5e02\u573a\u8d44\u8baf · 2026/10/8
• 评级变动
  Jefferies Maintains SANOFI(SNYNF.US) With Buy Rating, Cuts Target Price to $112.39
  \u5e02\u573a\u8d44\u8baf · 2026/10/1
• 公司公告
  Sanofi | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.2%)
  SEC · 2024/2/7
• 评级变动
  Deutsche Bank Maintains SANOFI(SNYNF.US) With Buy Rating, Cuts Target Price to $110.87
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• 评级变动
  RBC Capital Maintains SANOFI(SNYNF.US) With Hold Rating, Cuts Target Price to $92.32
  \u5e02\u573a\u8d44\u8baf · 2026/9/15
• 评级变动
  Deutsche Bank Maintains SANOFI(SNYNF.US) With Buy Rating, Raises Target Price to $110.07
  \u5e02\u573a\u8d44\u8baf · 2026/9/2
• 评级变动
  RBC Capital Initiates SANOFI(SNYNF.US) With Hold Rating, Announces Target Price $93.06
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• 评级变动
  UBS Maintains SANOFI(SNYNF.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/17

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。